Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus

Vaccine

Volumn 27, Issue 33, 2009, Pages 4434-4438

  Guthrie, Alan J ^a   Quan, Melvyn ^a   Lourens, Carina W ^a   Audonnet, Jean Christophe ^b   Minke, Jules M ^b   Yao, Jiansheng ^c   He, Ling ^c   Nordgren, Robert ^b   Gardner, Ian A ^d   MacLachlan, N James ^e  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Sanofi Pasteur   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

African horse sickness; Canarypox virus; Horses; Vaccine

Indexed keywords

ALVAC; CAPSID PROTEIN; HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PROTEIN VP2; PROTEIN VP5; RECOMBINANT CANARYPOX VIRUS VECTOR VACCINE; SYNTHETIC DNA; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

AFRICAN HORSE SICKNESS VIRUS; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CANARYPOX VIRUS; CONTROLLED STUDY; EDEMA; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GENE EXPRESSION; HORSE; HORSE DISEASE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H3N8; MALE; NONHUMAN; ORBIT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; SEROLOGY; SEROTYPE; THROMBOCYTOPENIA; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS VIRULENCE;

AFRICAN HORSE SICKNESS; AFRICAN HORSE SICKNESS VIRUS; ANIMALS; ANTIBODIES, VIRAL; CANARYPOX VIRUS; CAPSID PROTEINS; CELLS, CULTURED; CRICETINAE; FEMALE; HORSES; MALE; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 67649306196     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.044     Document Type: Article

References (39)

1. Theiler A. African horse sickness (pestis equorum). Sci Bull 19 (1921) 1-29
2. Guthrie A.J. African horse sickness. In: Sellon D.C., and Long M.T. (Eds). Equine infectious diseases (2007), Saunders Elsevier, St. Louis 164-171
3. Bayley T.B. Notes on the horse-sickness at the Cape of Good Hope in 1854-55 (1856), Saul Solomon & Co., Cape Town
4. Alexander R.A. The immunization of horses and mules against Horsesickness by means of the neurotropic virus of mice and guinea-pigs. Onderstepoort J Vet Sci Anim Ind 2 (1934) 375-391
5. von Teichman B.F., and Smit T.K. Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals. Vaccine 26 (2008) 5014-5021
6. Dubourget P., Preaud J.M., Detraz N., Lacoste F., Fabry A.C., Erasmus B.J., et al. Development, production, and quality control of an industrial inactivated vaccine against African horse sickness virus serotype 4. In: Walton T.E., and Osburn B.I. (Eds). Bluetongue, African horse sickness and related orbiviruses (1992), CRC Press, Boca Raton 874-886
7. Verwoerd D.W., Huismans H., and Erasmus B.J. Orbiviruses. In: Fraenkel-Conrat H., and Wagner R.R. (Eds). Comprehensive virology (1979), Plenum Press, London 285-345
8. Howell P.G. The isolation and identification of further antigenic types of African horsesickness virus. Onderstepoort J Vet Res 29 (1962) 139-149
9. McIntosh B.M. Immunological types of horsesickness virus and their significance in immunization. Onderstepoort J Vet Res 27 (1958) 465-539
10. Grubman M.J., and Lewis S.A. Identification and characterization of the structural and nonstructural proteins of African horsesickness virus and determination of the genome coding assignments. Virology 186 (1992) 444-451
11. Roy P., Mertens P.P., and Casal I. African horse sickness virus structure. Comp Immunol Microbiol Infect Dis 17 (1994) 243-273
12. Burrage T.G., Tevejo R., Stone-Marschat M., and Laegreid W.W. Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. Virology 196 (1993) 799-803
13. Martinez-Torrecuadrada J.L., and Casal J.I. Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus. Virology 210 (1995) 391-399
14. Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25 (2007) 672-678
15. MacLachlan N.J., Balasuriya U.B., Davis N.L., Collier M., Johnston R.E., Ferraro G.L., et al. Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. Vaccine 25 (2007) 5577-5582
16. House C., House J.A., and Mebus C.A. A review of African horse sickness with emphasis on selected vaccines. Ann N Y Acad Sci 653 (1992) 228-232
17. House J.A. Recommendations for African horse sickness vaccines for use in nonendemic areas. Rev Elev Med Vet Pays Trop 46 (1993) 77-81
18. House J.A. Future international management of African horse sickness vaccines. Arch Virol Suppl 14 (1998) 297-304
19. Nurton J.P., Guthrie A.J., and Howell P.G. Development and preliminary validation of an inactivated African horse sickness virus serotype 4 vaccine. Proceedings of the annual congress of the Equine Practitioners Group of the South African Veterinary Association, vol. 33 (2001) 129
20. Quan M., Van Vuuren M., Howell P.G., Groenewald D., and Guthrie A.J. Molecular epidemiology of the African horse sickness virus S10 gene. J Gen Virol 89 (2008) 1159-1168
21. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl (2004) 221-230
22. Piccini A., Perkus M.E., and Paoletti E. Vaccinia virus as an expression vector. Methods Enzymol 153 (1987) 545-563
23. Maree S., and Paweska J.T. Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera. J Virol Methods 125 (2005) 55-65
24. Minke J.M., Toulemonde C.E., Coupier H., Guigal P.M., Dinic S., Sindle T., et al. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am J Vet Res 68 (2007) 213-219
25. Howell P.G., Groenewald D.M., Visage C.W., Bosman A., Coetzer J.A.W., and Guthrie A.J. The classification of seven serotypes of equine encephalosis virus and the prevalence of homologous antibody in horses in South Africa. Onderstepoort J Vet Res 69 (2002) 79-93
26. Gould E.A., and Higgs S. Impact of climate change and other factors on emerging arbovirus diseases. Trans R Soc Trop Med Hyg 103 (2009) 109-121
27. Purse B.V., Brown H.E., Harrup L., Mertens P.P., and Rogers D.J. Invasion of bluetongue and other orbivirus infections into Europe: the role of biological and climatic processes. Rev Sci Technol 27 (2008) 427-442
28. Wilson A., Mellor P.S., Szmaragd C., and Mertens P.P. Adaptive strategies of African horse sickness virus to facilitate vector transmission. Vet Res 40 (2008) 1-16
29. ProMED-mail. Equine encephalosis-Israel: 2008. ProMED-mail 2009; 1 April: 20090401.1254. http://www.promedmail.org [accessed 02.04.2009].
30. Stone-Marschat M.A., Moss S.R., Burrage T.G., Barber M.L., Roy P., and Laegreid W.W. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Virology 220 (1996) 219-222
31. Scanlen M., Paweska J.T., Verschoor J.A., and Van Dijk A.A. The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant. Vaccine 20 (2002) 1079-1088
32. Du Plessis M., Cloete M., Aitchison H., and Van Dijk A.A. Protein aggregation complicates the development of baculovirus-expressed African horsesickness virus serotype 5 VP2 subunit vaccines. Onderstepoort J Vet Res 65 (1998) 321-329
33. Roy P., Bishop D.H., Howard S., Aitchison H., and Erasmus B. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. J Gen Virol 77 (1996) 2053-2057
34. Martinez-Torrecuadrada J.L., Diaz-Laviada M., Roy P., Sanchez C., Vela C., Sanchez-Vizcaino J.M., et al. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. J Gen Virol 77 (1996) 1211-1221
35. Romito M., Du Plessis D.H., and Viljoen G.J. Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. Onderstepoort J Vet Res 66 (1999) 139-144
36. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., and Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 25 (2007) 5606-5612
37. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., et al. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec 153 (2003) 141-145
38. ProMED-mail. Bluetongue-Europe (07): BTV-6, BTV-11 update. ProMED-mail 2009; 4 March: 20090304.0888. http://www.promedmail.org [accessed 26.04.2009].
39. Savini G., MacLachlan N.J., Sanchez-Vizcaino J.M., and Zientara S. Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 31 (2008) 101-120